Table 2.
Descriptive data for cohort studies included in the meta-analysis.
| Author | Year | Country | AID | NDD | N of parents with AID | N of parents with AID and offspring with NDD | N of parents without AID | N of parents without AID and offspring with NDD |
|---|---|---|---|---|---|---|---|---|
| Ji | 2018 | Sweden | T1D | ADHD | 6700 + 15,615 | NR | 993,442 + 1,380,829 | NR |
| Rom | 2018 | Denmark | RA | ASD | 15,615 + 13,556 | 84 | 1,380,829 + 1,904,167 | 18,116 |
| Andersen | 2014 | Denmark | IBD | ASD | 6330 + 6700 | 62 | 1,911,393 + 99,442 | 16,050 |
| Lee | 2021 | Taiwan | Sjogren, SLE, RA, Systemic sclerosis, Idiopathic inflammatory myositis, T1D, MS, Myasthenia gravis, Psoriasis, IBD, Vasculitis, AS, Behçet | ADHD | 1990 | 117 + 61 | 706,527 | 28,092 + 28,148 |
| Lee | 2021 | Taiwan | Sjogren, SLE, RA, Systemic sclerosis, Idiopathic inflammatory myositis, T1D, MS, Myasthenia gravis, Psoriasis, IBD, Vasculitis, AS, Behçet | ASD | 1327 | 13 + 10 | 707,190 | 4493 + 4496 |
Note that for Lee, we have deliberately shown two different lines because they studied two neurodevelopmental outcomes.
AID autoimmune or inflammatory disorders, NDD neurodevelopmental disorders, T1D type 1 diabetes, RA rheumatoid arthritis, IBD inflammatory bowel disease, ADHD attention deficit/hyperactivity disorders, ASD autism spectrum disorders.